Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is the first study to be conducted in humans for RTI-336, a new chemical entity, with
evaluations focusing on the safety, tolerability, and pharmacokinetics of RTI-336 following
administration of single, oral doses. RTI-336 is a novel dopamine transporter inhibitor of
the 3-phenyltropane class, and is currently being developed by RTI International as a
potential pharmacotherapy to treat cocaine dependence. Data from this study will be used to
plan and define dose ranges for subsequent studies.